Cero Therapeutics Files 8-K Report
Ticker: CEROW · Form: 8-K · Filed: Feb 12, 2025 · CIK: 1870404
Sentiment: neutral
Topics: 8-K, corporate-event
Related Tickers: CERO
TL;DR
Cero Therapeutics filed an 8-K on Feb 12, 2025. Details TBD.
AI Summary
On February 12, 2025, Cero Therapeutics Holdings, Inc. filed an 8-K report. The filing indicates a change in the company's status or operations, though specific details regarding the event are not provided in this excerpt. The company, formerly known as Phoenix Biotech Acquisition Corp., is incorporated in Delaware and operates in the Biological Products sector.
Why It Matters
This filing signals a material event for Cero Therapeutics Holdings, Inc., requiring disclosure to investors and the public. Investors should review the full filing for details on the reported event.
Risk Assessment
Risk Level: medium — An 8-K filing indicates a significant event, but without specific details, the risk level is moderate as the nature of the event is unknown.
Key Players & Entities
- CERO THERAPEUTICS HOLDINGS, INC. (company) — Registrant
- Phoenix Biotech Acquisition Corp. (company) — Former Company Name
- February 12, 2025 (date) — Date of Report
FAQ
What specific event prompted the filing of this 8-K report by Cero Therapeutics Holdings, Inc. on February 12, 2025?
The provided excerpt does not specify the exact event that triggered the 8-K filing on February 12, 2025. It is categorized under 'Other Events'.
What was Cero Therapeutics Holdings, Inc. formerly known as?
Cero Therapeutics Holdings, Inc. was formerly known as Phoenix Biotech Acquisition Corp.
In which state is Cero Therapeutics Holdings, Inc. incorporated?
Cero Therapeutics Holdings, Inc. is incorporated in Delaware.
What is the Standard Industrial Classification (SIC) code for Cero Therapeutics Holdings, Inc.?
The SIC code for Cero Therapeutics Holdings, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
What is the business address of Cero Therapeutics Holdings, Inc.?
The business address of Cero Therapeutics Holdings, Inc. is 201 Haskins Way, Suite 230, South San Francisco, CA 94080.
Filing Stats: 493 words · 2 min read · ~2 pages · Grade level 13.7 · Accepted 2025-02-12 16:10:13
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CERO NASDAQ Capital Marke
Filing Documents
- ea0230890-8k_cerotherap.htm (8-K) — 26KB
- 0001213900-25-012891.txt ( ) — 240KB
- cero-20250212.xsd (EX-101.SCH) — 4KB
- cero-20250212_def.xml (EX-101.DEF) — 26KB
- cero-20250212_lab.xml (EX-101.LAB) — 36KB
- cero-20250212_pre.xml (EX-101.PRE) — 25KB
- ea0230890-8k_cerotherap_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events. On February 12, 2025, CERo Therapeutics Holdings, Inc. (the "Company") received a letter from the Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Requirement") and has applied and been moved to the Nasdaq Capital Market, as required by the panel convened by Nasdaq (the "Nasdaq Panel"). Regaining compliance with the Bid Price Requirement is one of the conditions set forth by the Nasdaq Panel in its previously disclosed decision granting the Company's request for an extension (the "Extension") to regain compliance with certain Nasdaq continued listing requirements until April 22, 2025. The Company continues to make progress towards satisfaction of the other conditions. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 12, 2025 CERO THERAPEUTICS HOLDINGS, INC. By: /s/ Chris Ehrlich Name: Chris Ehrlich Title: Chief Executive Officer 2